Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study

27 May 2024

Abstract excerpt

BACKGROUND: Tailoring antidepressant drugs (AD) to patients' genetic drug-metabolism profile is promising. However, literature regarding associations of ADs' treatment effect and/or side effects with drug metabolizing genes CYP2D6 and CYP2C19 has yielded inconsistent results. Therefore, our aim was to longitudinally investigate associations between CYP2D6 (poor, intermediate, and normal) and CYP2C19 (poor,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics and Drug Metabolism
Share to Treatment of Major Depression
Share to Tryptophan and brain disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38797832
DOI: 10.1186/s12888-024-05764-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory studyPMID 38797832Read ↗

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity Read ↗

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.Semantic proximity Read ↗

Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.Semantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

Impact of CYP2C19 Genotype on Sertraline and Escitalopram Exposure and Antidepressant Switching Rate: A Retrospective Cohort Study of Chinese Han Patients.Semantic proximity Read ↗

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.Semantic proximity Read ↗

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK BiobankSemantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

Antidepressant switching as a proxy phenotype for drug non-response: investigating clinical, demographic and genetic characteristicsSemantic proximity Read ↗

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.